Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Cited In for PubMed (Select 15292285)

1.

Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution.

Aboelnaga EM, Ahmed RA.

Cancer Biol Med. 2015 Mar;12(1):53-9. doi: 10.7497/j.issn.2095-3941.2015.0005.

2.

Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

van der Horst-Schrivers AN, Sluiter WJ, Muller Kobold AC, Wolffenbuttel BH, Plukker JT, Bisschop PH, de Klerk JM, Al Younis I, Lips P, Smit JW, Brouwers AH, Links TP.

PLoS One. 2015 Mar 20;10(3):e0120184. doi: 10.1371/journal.pone.0120184. eCollection 2015.

3.

Retrospective Analysis of 255 Papillary Thyroid Carcinomas ≤2 cm: Clinicohistological Features and Prognostic Factors.

Marques P, Leite V, Bugalho MJ.

Eur Thyroid J. 2014 Dec;3(4):258-63. doi: 10.1159/000369133. Epub 2014 Dec 6.

4.

Recurrence of papillary thyroid cancer after optimized surgery.

Grant CS.

Gland Surg. 2015 Feb;4(1):52-62. doi: 10.3978/j.issn.2227-684X.2014.12.06. Review.

5.
6.

MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation.

Liu Z, Xun X, Wang Y, Mei L, He L, Zeng W, Wang CY, Tao H.

Am J Transl Res. 2014 Jan 15;6(2):147-54. eCollection 2014.

7.

Acute severe hypothyroidism is not associated with hyponatremia even with increased water intake: a prospective study in thyroid cancer patients.

Hammami MM, Almogbel F, Hammami S, Faifi J, Alqahtani A, Hashem W.

BMC Endocr Disord. 2013 Jul 31;13:27. doi: 10.1186/1472-6823-13-27.

8.

New developments in the diagnosis and treatment of thyroid cancer.

Schneider DF, Chen H.

CA Cancer J Clin. 2013 Nov-Dec;63(6):374-94. doi: 10.3322/caac.21195. Epub 2013 Jun 24. Review.

9.

Remnant uptake as a postoperative oncologic quality indicator.

Schneider DF, Ojomo KA, Chen H, Sippel RS.

Thyroid. 2013 Oct;23(10):1269-76. doi: 10.1089/thy.2012.0451. Epub 2013 Jul 17.

10.

Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.

Sohn SY, Choi JY, Jang HW, Kim HJ, Jin SM, Kim SW, Suh S, Hur KY, Kim JH, Chung JH, Kim SW.

Thyroid. 2013 Jun;23(6):741-7. doi: 10.1089/thy.2012.0136.

11.

To treat or not to treat: the role of adjuvant radioiodine therapy in thyroid cancer patients.

Carballo M, Quiros RM.

J Oncol. 2012;2012:707156. doi: 10.1155/2012/707156. Epub 2012 Nov 1.

12.

The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Kogai T, Brent GA.

Pharmacol Ther. 2012 Sep;135(3):355-70. doi: 10.1016/j.pharmthera.2012.06.007. Epub 2012 Jun 29. Review.

13.

Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma.

Tanaka K, Sonoo H, Saito W, Ohta Y, Shimo T, Sohda M, Yamamoto Y, Kurebayashi J.

ISRN Endocrinol. 2011;2011:308029. doi: 10.5402/2011/308029. Epub 2011 Mar 29.

14.

The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Rivkees SA, Mazzaferri EL, Verburg FA, Reiners C, Luster M, Breuer CK, Dinauer CA, Udelsman R.

Endocr Rev. 2011 Dec;32(6):798-826. doi: 10.1210/er.2011-0011. Epub 2011 Aug 31. Review.

15.

Use of radioactive iodine for thyroid cancer.

Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ.

JAMA. 2011 Aug 17;306(7):721-8. doi: 10.1001/jama.2011.1139.

16.

Prognostic factors of a good response to initial therapy in children and adolescents with differentiated thyroid cancer.

Vaisman F, Bulzico DA, Pessoa CH, Bordallo MA, Mendonça UB, Dias FL, Coeli CM, Corbo R, Vaisman M.

Clinics (Sao Paulo). 2011;66(2):281-6.

17.

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.

Kukulska A, Krajewska J, Gawkowska-Suwińska M, Puch Z, Paliczka-Cieslik E, Roskosz J, Handkiewicz-Junak D, Jarzab M, Gubała E, Jarzab B.

Thyroid Res. 2010 Nov 1;3(1):9. doi: 10.1186/1756-6614-3-9.

18.

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.

Biondi B, Pulcrano M, Pagano L, Lombardi G.

Biologics. 2009;3:9-13. Epub 2009 Jul 13.

19.

Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma?

Choi SJ, Kim TY, Lee JC, Shong YK, Cho KJ, Ryu JS, Lee JH, Roh JL, Kim SY.

Clin Exp Otorhinolaryngol. 2008 Mar;1(1):41-5. doi: 10.3342/ceo.2008.1.1.41. Epub 2008 Mar 20.

20.

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R.

J Clin Oncol. 2009 Jun 20;27(18):2977-82. doi: 10.1200/JCO.2008.20.1426. Epub 2009 May 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk